文献速递流行病学与生物统计临床试验与 GCP

贝叶斯分层EMAX模型用于早期疗效临床试验的剂量-反应关系

Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials.
PubMed 文献 · Stat Med · 2019-05-09

II期剂量探索试验旨在确定优于对照的剂量。独立模型不利用相关剂量信息,EMAX模型利用预设剂量-反应结构提高效能,但规划时需处理非单调趋势风险。作者提出在EMAX模型中加入分层参数以借用不同剂量的疗效信息,比较独立模型、EMAX模型和分层EMAX模型及固定随机与响应自适应随机两种设计,并以重型创伤性脑损伤患者随机试验为例。

要点

  • 分层EMAX模型通过借用相邻剂量信息提高剂量-反应估计效率。
  • 比较独立模型、EMAX模型与分层EMAX模型及固定随机与响应自适应随机两种设计。
  • 以重型创伤性脑损伤患者随机试验为激励性示例。

核心结论

  • 作者提出分层EMAX模型,通过在EMAX模型中加入分层参数,允许在估计某一剂量的疗效时借用其他剂量的疗效信息。

研究设计与样本

  • 方法学研究,比较独立模型、EMAX模型和分层EMAX模型三种模型以及固定随机设计和响应自适应随机设计两种设计策略,并以重型创伤性脑损伤患者随机试验为示例。

主要发现

  • 独立模型不对剂量-反应关系施加结构,不能有效利用相关剂量的信息。
  • EMAX模型利用预设的剂量-反应结构提高效能,但规划临床试验设计时可能存在轻微的非单调趋势风险。
  • 分层EMAX模型通过增加分层参数,允许在估计某一剂量的疗效时借用其他剂量的疗效信息。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A primary goal of a phase II dose-ranging trial is to identify a correct dose before moving forward to a phase III confirmatory trial. A correct dose is one that is actually better than control. A popular model in phase II is an independent model that puts no structure on the dose-response relationship. Unfortunately, the independent model does not efficiently use information from related doses. One very successful alternate model improves power using a pre-specified dose-response structure. Past research indicates that EMAX models are broadly successful and therefore attractive for designing dose-response trials. However, there may be instances of slight risk of nonmonotone trends that need to be addressed when planning a clinical trial design. We propose to add hierarchical parameters to the EMAX model. The added layer allows information about the treatment effect in one dose to be "borrowed" when estimating the treatment effect in another dose. This is referred to as the hierarchical EMAX model. Our paper compares three different models (independent, EMAX, and hierarchical EMAX) and two different design strategies. The first design considered is Bayesian with a fixed trial design, and it has a fixed schedule for randomization. The second design is Bayesian but adaptive, and it uses response adaptive randomization. In this article, a randomized trial of patients with severe traumatic brain injury is provided as a motivating example.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Gajewski BJ, Meinzer C, Berry SM, et al. Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials. Stat Med. 2019. PMID: 31070807. doi:10.1002/sim.8167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。